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Phlorizin.induced glycosuria does not prevent gentamicin nephrotoxic.
ity in rats. Because rats with streptozotocin-induced diabetes mellitus
(DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have
suggested that this may in part be responsible for their resistance to
gentamicin-induced acute renal failure (ARF). The protection from
gentamicin nephrotoxicity was studied in non-diabetic rats with chronic
solute diuresis induced by blockage of tubular glucose reabsorption
with phlorizin (P). DM rats with mild glycosuria (similar in degree to
that of the P treated animals) were also studied. Unanesthetized adult
female, Sprague-Dawley rats were divided in four groups and studied
for 15 days. Group I (P alone) received P, 360 mg/day, for 15 days;
Group II (P + gentamicin); Group III (gentamicin alone) and Group IV
(mild DM + gentamicin). Nephrotoxic doses (40 mg/kg body wt/day) of
gentamicin were injected during the last nine days of study to the
animals of groups II to IV. In Group I, P induced a moderate and stable
glycosuria (3.9 0.1 g/day, SE), and no functional or morphologic
evidence of renal dysfunction (baseline Cr 2.1 0.1 mI/mm, undetect-
able lysozymuria) or damage (tubular necrosis score [maximum 41,
zero). In Group II, P did not prevent gentamicin-ARF (maximal
decrease in C at day 9, 89%, P < 0.001; peak lysozymuria, 1863 321
gIday; and tubular necrosis score, 3.9 0.1). These values were not
different from those of Group III: maximal decrease in C. 73% (° <
0.001); lysozymuria, 2147 701 1kg/day; tubular necrosis score, 3.8
0.1. In marked contrast, Group IV DM rats with mild glycosuria (4.1
1.0 g/day) were protected from gentamicin toxicity: maximal decrease
in Cr was 10% (from 2.0 0.1 to 1.8 0.1 mI/mm; P < 0.001 vs.
Groups II and III); peak lysozymuria, 31 31 j.g/day (P < 0.001 vs.
Groups H and III); tubular necrosis score, 0.8 0.4 (P < 0.001 vs.
Groups LI and III). No differences in renal cortical gentamicin accumu-
lation were found between Groups II, III and IV (360 20, 395 25
and 493 55 .tgIg wet tissue, respectively). The later finding most likely
resulted from an underestimation of gentamicin tissue levels in Groups
II and LII due to tubular necrosis. We conclude that P alone does not
result in renal dysfunction or damage. The protection against gentami-
cin-ARF of DM rats with mild glycosuria, and the lack of protection in
the P + G treated rats were independent of the glycosuria, solute
diuresis and urine flow rate. Thus, the resistance afforded by the
diabetic state to gentamicin-ARF is not explained by the enhanced
solute cliuresis or altered glucose transport.
Previous studies from our laboratory have demonstrated a
complete functional and morphologic protection from acute
renal failure (ARF) induced by nephrotoxic doses of gentamicin
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in the rat with untreated diabetes mellitus [1, 2]. This resistance
was associated with an early and marked decreased accumula-
tion of gentamicin in the renal cortex of the diabetic animals [1—
31, and was independent of the duration of diabetes [3]. Our
findings have been recently confirmed by others [4—6], who also
found lower renal cortical aminoglycoside levels in diabetic rats
when gentamicin [4, 5] or netilmicin [6] was given to Sprague-
Dawley [4, 61 or male Fischer 344 rats [5].
The factors responsible for the preservation of renal function
in the diabetic rat treated with gentamicin remain to be fully
uncovered, but marked glycosuria and osmotic diuresis were
initially suggested by us as likely explanations [1]. Others have
demonstrated that osmotic diuresis induced by oral isosorbide
did not account for the protective effect in diabetic [5] or
nondiabetic rats [7]. Since the renal uptake of gentamicin
occurs mainly in the proximal convoluted tubule [8—10], it is
conceivable that the marked glycosuria exhibited by the un-
treated diabetic rat might interfere with the incorporation of
gentamicin, leading to decreased intracellular accumulation and
less cellular injury.
In order to study the effect of glycosuria on renal gentamicin
handling in non-diabetic animals and its possible protective role
against gentamicin nephrotoxicity, we induced chronic renal
glycosuria with phlorizin, a competitive inhibitor of glucose
transport in the proximal tubule [11, 12], in non-diabetic rats
subsequently injected with gentamicin. Their nephrotoxic re-
sponse to gentamicin was compared to that of non-glycosuric
control animals and rats with mild diabetes mellitus and similar
degree of glucose excretion. This model was specifically se-
lected to avoid: (a) the intravenous or oral administration of
solute (hypertonic glucose and mannitol, or isosorbide [5, 7],
respectively) and the hemodynamic consequences of its acute
or rapid administration; and (b) the development of hypergly-
cemia.
The phlorizin-induced glycosuria did not protect the non-
diabetic rats from gentamicin-induced ARF. Thus, glycosuria
per Se, or a moderate degree of solute diuresis, does not appear
to explain the resistance conferred on diabetic rats against the
nephrotoxic effects of this aminoglycoside.
Methods
Adult female Sprague-Dawley rats (Charles River Breeding
Laboratory, Wilmington, Massachusetts, CD strain) weighing
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150 to 250 g were used. The animals were housed in individual
metabolic cages, fed a standard rat chow and had free access to
tap water, as previously described [11.
The four groups of animals studied and the experimental
protocol employed are outlined in Figure 1. Renal glycosuria
was induced in two groups: Group I (phiorizin alone, PHL, N
9), and Group 1I(phlorizin + gentamicin, PHL + U, N = 10).
Phlorjzjn (Sigma Chemical Co., Saint Louis, Missouri, USA,
lot # 68C-0465) was dissolved in propylene-glycol (JT Baker
Chemical Co.) and injected subcutaneously in two equally
divided doses, at a daily dose of 360 mg for 15 days. The
selection of the dose and route of administration was based on
preliminary experiments that proved the efficacy in blocking
renal glucose reabsorption without causing any apparent ad-
verse effect on glomerular filtration rate (GFR). Group III
(gentamicin alone, G) consisted of 10 rats that received injec-
tions of the vehicle for phiorizin, propylene-glycol, 1 mI/day
(also given to rats in Groups I and II). Group IV (mild diabetes
+ gentamicin, DM + G) consisted of diabetic rats with glycos-
uria of a magnitude (about 4 g per day) similar to that of
phiorizin-treated animals (Groups I and II). The mild glycosuria
in the DM rats was achieved by either of two methods: (a) by
the intravenous administration of streptozotocin given at a
single low dose of 35 mg/kg body weight three to four weeks
prior to study; (b) by injecting streptozotocin at the dose of 65
mg/kg body weight [1—31. In the latter animals, miniosmotic
pumps (AIza Co., Palo Alto, California, USA) filled with lente
insulin (Eli Lilly and Co., Indianapolis, Indiana, USA) were
implanted subcutaneously and set to deliver subtherapeutic
doses of insulin (16 U per kg/day) for 14 to 16 days [13].
Twenty-four hour urine glucose excretion rates were measured
at frequent intervals in Groups I, II and IV.
An adaptive period of three to four days preceded the
initiation of the experiments. At the end of this period, urine
Fig. 1. Outline of experimental protocols.
Note that in addition to Group III (gentamicin
alone), Group I (phiorizin alone) and II
(phlorizin + gentamicin) also received
propylene glycol. The arrows at the bottom
indicate when blood sampling, 24-hour urine
collections and balance studies were carried
Out.
and blood samples were collected, and are referred to as
baseline zero (BO). A second six day period followed. During
this part of the protocol, the phiorizin-induced glycosuria and
polyuria (Groups I and II), and mild diabetes mellitus (Group
IV) were established as described above (Fig. 1). On days 5 and
6, blood samples and 24-hour urine collections were obtained.
These results were averaged and are referred to as baseline (B).
During the final phase of the experiment (induction of neph-
rotoxicity, Fig. 1), gentamicin sulfate (Schering Corporation,
Kenilworth, New Jersey, USA) was given subcutaneously at a
dose of 40 mg/kglday in two equally divided doses (8 a.m. and
4 p.m.) for nine days to Groups II, III and IV. Administration of
phiorizin (Groups I and II), propylene-glycol (Groups I, II and
III) and insulin (Group IV) continued throughout this period.
Twenty-four hour urine collections were obtained on days 3, 6
and 9. At the end of each collection, blood was obtained via tail
bleeding directly into heparinized tubes. Body weights and
water and food consumption were also recorded.
On completion of day 9, the animals were anesthetized with
mactin (Promonta, Hamburg, FRG) and the right kidney was
perfused via the aorta with oxygenated Ringer's solution, and
rapidly removed and prepared for determination of the tissue
content of gentamicin as shown before [1]. The left kidney was
perfused in situ, first with Ringer's and then with Karnovsky's
fixative and removed for light microscopic examination.
Plasma and urine sodium and potassium concentrations were
determined with an IL flame photometer, osmolality was mea-
sured with a Fiske osmometer, and non-fasting plasma and
urine glucose by the glucose oxidase method utilizing a Beck-
man glucose analyzer. Plasma and urine creatinine was deter-
mined by the method of Hare [14]. The validity of measuring
creatinine by this method in the presence of high urinary
glucose concentrations has been previously shown in our
laboratory [1]. Creatinine clearance (Ccr), osmolal clearance
Group I
(Phlorizin)
Group II
(Phlorizin +
Gentamicin)
Group Ill
(Gentamicin)
Group IV(Mild DM +
Gentamicin)
Phlorizin 360 mg/day
I
Phlorizin (360 mg/day>
I
+ Gentamicin (40 mg/kg/day) 4
Propylene glycol (1 mi/day)
I
+ 4 Gentamicin (40 mg/kg/day)
4'
4
insulin (16 U/kg/day)
+ Gentamicin (40 mg/kg/day) I
Adaptation Baseline induction of
(3—4 days)III (6 days)11111 IIInephrotoxicity (9 days)11111
Day 9
Gouvea et a!: Glycosuria and gentamicin nephrotoxicity 1043
Table 1. Blood and renal function van ables in rats treated with phlorizin for 15 days (Group I)
Baseline
zero Baseline Day 3 Day 6 Day 9
Body weight g 222 6 NS 222 5 225 5b 232 5b 235 5b
Plasma creatinine 0.35 0.01 P < 0.001 0.28 0.01 0.26 0.01 0.22 0.01c 0.21 O.OI
mg/di
Plasma glucose 138 5 P < 0.05 128 4 127 4 128 4 121 2
mg/di
Plasma sodium 147 2 NS 146 1 147 1 144 1 146 1
mEqlliter
Plasma potassium 6.2 0.5 NS 6.2 0.5 5.6 0.1 5.3 0.1 5.9 0.2
mEq/iiter
Urine volume 10 1 P < 0.001 38 2 38 2 42 2 37 2
mi/day
Ccr mi/mm 1.6 0.1
Urine glucose 3.2 0.2
P <0.005
P < 0.001
2.1 0.1
4129 152
2.1 0.1
4103 136
2.8 0.2c
4288 145"
2.9 0.lc
3944 139
mg/day
Urine sodium 1 0.1 P < 0.001 1.3 0.1 1.4 01d 1.2 0.1 1.7 1
mEq/day
Urine osmolality 1868 80 P < 0.005 1478 52 1526 47 1358 63 1507 55
mOsm/kg H20
Osmolal clearance 43 3 P < 0.001 125 5 129 5 130 4 122 6
i.d/min
Fractional 0.2 0.1 P < 0.001 109 4 107 3 85 3C 77 2C
excretion of
glucose %
a P> 0.05
b P < 0.025 to 0.005 versus Baseline
P < 0.001 versus Baseline
d P < 0.05 versus Baseline
(Cosm) and fractional excretion of glucose (FEG) were calcu-
lated using standard equations. Urine lysozyme (muramidase)
was measured by a radial diffusion technique (Hallstad Lab,
Chaska, Minnesota, USA) and the results are expressed in sg
per 24 hours. The gentamicin content of the renal cortex was
measured in duplicate by an enzymatic radiochemical assay
('4C gentamicin, P.L. Biochemicals, Inc., Milwaukee, Wiscon-
sin, USA) and the results expressed in jsg!g of wet tissue [1].
Light microscopy coded slides stained with hematoxylin-
eosin were examined by one of the authors (VP) without prior
knowledge of their origin. Proximal tubular damage was graded
from 0 to 4 according to the following scale: 0 = no necrosis; 1
= mild, usually single cell necrosis in sparse tubules; 2 =
moderate, sparse tubules showing more than one cell involved;
3 = marked, tubules in almost every high power field exhibiting
necrosis; and 4 = massive, total necrosis. For each group, the
results were averaged and expressed as a tubular necrosis
score. Quantitative differences between the various groups
were analyzed by nonparametric statistical methods (Mann-
Whitney U test).
Values are presented as mean SEM. Statistical analyses of
paired and unpaired data were performed according to paramet-
ric and non-parametric techniques [15, 16]. One way analysis of
variance (ANOVA) was performed among the four groups.
When the ANOVA was significant (P < 0.05), a Newman-Keuls
multiple range test was performed to identify which groups
were statistically different.
Results
Baseline blood and renal function values
Phiorizin-treated rats (Groups I and II). For the purpose of
simplification only detailed data of Group I are presented (Table
1). Tubular glucose reabsorption was effectively blocked by
phiorizin in Groups I and II rats. At baseline, glycosuria
averaged 4.1 0.1, and 3.4 0.2 g/day (P < 0.005 vs. BO),
with a corresponding FE0 of 109 4 and 91 7% (P < 0.001
vs. BO), respectively. Non-fasting plasma glucose levels de-
creased slightly from BO levels in the PHL group (Table 1),
whereas no changes were seen in the PHL + G rats (Table 2).
There was a fourfold increase in urine volume for groups I and
II. As expected Csm and sodium excretion increased as well.
After phlorizin a 22% increase in Cr (P < 0.005) was accom-
panied by a concomitant decrease in plasma creatinine (P <
0.00 1) in the PHL group. This elevation in Cr was not detected
after six days of phlorizin treatment in the PHL + G rats. It
should be noted, however, that prior to the initiation of genta-
micin administration, plasma creatinine and Cr were similar in
these two groups (Table 2).
Rats with mild diabetes meilitus (Group IV). Marked vari-
ability in the degree of glycosuria was exhibited by the DM rats,
making it difficult to obtain a group of mild DM animals with
rates of glucose excretion sufficiently stable and similar to those
of the phlorizin-treated rats. Only one of the rats injected with
a low dose of streptozotocin was suitable for the study. All the
others either lost their diabetes or developed severe glycosuria
(8 to 12 g/day). Somewhat better results were obtained with
administration of low doses of insulin to fully diabetic rats: of
the 10 animals that had osmotic minipumps implanted at BO,
four were selected for the continuation of the study.
As a group, these five animals had moderate hyperglycemia,
and glycosuric rates (4.1 1.0 g/day) similar to those of the
phlorizin-treated groups. Baseline urine volume was also not
different between these groups, the DM rats, however, had
higher Cosm and excreted more sodium than groups I and II
S
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Table 2. Comparative changes from baseline after 9 days of gentamicin administration
Groups
Number of
animals
Phlorizin (I)
9
Phiorizin-
gentamicin
(H)
10
Gentamicin
(LII)
10
Mild DM +
gentamicin
(IV)
5
ANOVA
for all
groupsd
P value
Newman-Keuls multiple range test
I vs. II IL vs. III II vs. IV III vs. IV
Body weight
g
Ba 222 5
<0.00!
D9b 235 5
212 6
NS
211 6
209 4
<0.001
203 7
230 15
NS
245 7
NS
<0.001
NS NS NS NS
<0.05 NS <0.05 <0.05
Urine volume
mi/day
B 38 2
NS
D9 37 2
44 3
<0.025
32 3
16 2
<0.01
26 3
54 11
NS
32 5
<0.001
NS
NS <0.05 NS <0.05
NS NS NS NS
Plasma creatinine
irig/di
B 0.3 0.01
<0.001
D9 0.2 0.01
0.3 0.01
<0.001
1.9 0.3
0.3 0.01
<0.001
1.7 0.3
0.2 0.02
NS
0.3 0.04
NS
<0.001
NS NS NS NS
<0.05 NS <0.05 <0.05
Plasma glucose
mg/dl
B 128 4
NS
D9 121 2
132 3
<0.001
115 2
133 3
NS
136 9
411 42
<0.01
133 57
<0.001
NS
NS NS <0.05 <0.05
NS NS NS NS
Plasma sodium
mEq/iiter
B 146 I
NS
D9 146 1
146 1
<0.01
141 1
151 1
<0.001
145 1
146 1
NS
146 1
<0.001
<0.001
NS <0.05 NS <0.05
<0.05 <0.05 <0.05 NS
Cc,.
mi/mm
B 2.1 0.1
<0.001
D9 2.9 0.2
2.2 0.2
<0.001
0.24 0.04
1.6 0.1
<0.001
0.5 0.16
2.0 0.1
NS
1.8 0.1
<0.05
<0.001
NS <0.05 NS <0.05
<0,05 NS <0.05 <0.05
Urine glucose
mg/day
B 4129 152
NS
D9 3944 139
3438 200
<0.001
735 103
3 0.5
<0.01
33 8
4142 1040
NS
1591 726
<0.001
<0.001
NS <0.05 NS <0.05
<0.05 <0.05 <0.05 <0.05
Urine sodium
mEq/day
B 1.3 0.1
<0.001
D9 1.7 0.1
1.4 0.1
<0.005
0.8 0.1
0.9 0.04
NS
0.7 0.1
1.9 0.1
<0.05
1.4 0.2
<0.001
<0.001
NS <0.05 <0.05 <0.05
<0.05 NS <0.05 <0.05
Urine osmolality
mOsm/kg H20
B 1478 52
NS
D9 1507 55
1148 57
<0.001
597 44
1231 101
<0.001
501 42
1341 62
<0.025
1036 135
<0.05
<0.001
<0.05 NS NS NS
<0.05 NS <0.05 <0.05
Osmolal clearance
j4/min
B 125 5
NS
D9 122 6
110 5
<0.001
41 5
40 2
<0.001
25 3
151 3
<0.05
74 13
<0.001
<0.001
NS <0.05 <0.05 <0.05
<0.05 <0.05 <0.05 <0.05
a Baseline
b Ninth day after gentamicin administration (40 mg/kg body wt/day)
Nonsignificant P> 0.05
d One-way analyses of variance (ANOVA) among the four groups
When ANOVA was significant (0.05) a Newman-Keuls multiple range test was performed to identify which groups were statistically different(P  0.05).
Plasma glucose and urinary glucose declined throughout study: day 3 (267 56 mg/dl and 2034 656 mg/day) and day 6 (223 90 mg/dl and
2149 939 mg/day).
(Table 2). The Ce,. of the DM animals at baseline was similar to
that of the two phiorizin-treated groups.
Non-glycosuric rats (Group III). At baseline, the urine vol-
ume and Ce,. of group III animals were significantly lower than
those of the other groups. Urinary glucose excretion was
negligible, and sodium and solute excretion were also signifi-
cantly lower (Table 2).
Effect of phiorizin treatment on renal function and
morphology
The animals treated only with phlorizin (Group I), continued
their growth and maintained a stable polyuria throughout. The
group increased somewhat their water, food, sodium and po-
tassium intake (not shown). Plasma glucose, sodium, and
potassium concentrations remained essentially unchanged
(Table 1). In these normoglycemic glycosuric animals, as we
have observed previously in hyperglycemic glycosuric rats [1,
3], C increased as the study progressed (Fig. 2). Glycosuria
and osmolal clearance, however, remained essentially un-
changed. As expected from the glycosuria, urine osmolality
decreased significantly at baseline and remained stable thereaf-
ter. The progressive decrease in the estimated FE0 may have
reflected the stability of the glycosuria in the phase of an
increase in Cr combined with a slight decrease in plasma
glucose concentration (Table 1). Lysozymuria was never de-
tected in these animals. When their kidneys were examined by
light microscopy after 15 days of phiorizin administration, no
glomerular or tubular abnormalities were detected (tubular
necrosis score of 0). Thus, phlorizin treatment for two weeks
did not adversely affect renal function or morphology.
Renal function, renal cortical accumulation of gentamicin
and histological findings after treatment with gentamicin
Table 2 summarizes the data obtained at baseline and day 9
after gentamicin administration for all groups. Figure 2 illus-
trates the sequential changes in C. along the length of the
1.0 —
Fig. 2. Sequential changes in creatinine
clearance before and during gentamicin
administration (40 mg/kg/day for 9 days) in
Group II (•), III (A) and IV (A). Changes in
Group I (phlorizin alone [0)1, no gentamicin
injections) are also shown. The vertical bars
I I I I I I I I I ] indicate the SEM. For brevity, paired and
Baseline Day 3 Day 6 Day 9 unpaired P values are described in the text
zero and Tables 1 and 2.
study, and Figure 3 summarizes the maximal changes in Ccr,
peak lysozymuria, the tubular necrosis score and the renal
cortical gentamicin content for all groups.
The non-glycosuric animals treated only with gentamicin
(Group III) developed the typical findings of ARF. By day 6,
lysozymuria was detected (135 29 1zg/day), and GFR began to
decrease, as evidenced by a significant elevation of plasma
creatinine concentration to 0.6 0.06 mg/cu and a reduction in
Ccr to 1.0 0.1 ml/min, P <0.01, Fig. 2). By day 9, marked
worsening of renal function was documented, with plasma
creatinine reaching 1.7 0.3 mg/dl (P < 0.001) and C.
declining to a value 73% below baseline. In addition, there was
marked lysozymuria (2147 701 .tg/day; P < 0.01 from
baseline), and evidence of histological damage (Fig. 3). The
tubular necrosis score of these animals was 3.8 0.1. The
morphologic findings were limited to the proximal tubule, and
were similar to those previously described [1, 31. The rehal
cortical content of gentamicin was 395 25 zgIg wet tissue, a
value similar to those obtained in this laboratory with compa-
rable protocols [1, 3].
The response of the group II animals (PHL + G) to gentami-
cm administration was very similar to that of the gentamicin
alone Group III. The Cr began to decrease by day 6, achieving
a level similar to that of Group III rats (Fig. 3). Lysozymuria
also was detected at this time (36 24 cg/day). By day 9, the
Ccr had declined 89%, a value not different from that observed
in Group III animals. These animals remained glycosuric
throughout the experiment, albeit with a lower FEG (Table 2).
The significant decrease in glycosuria (P < 0.001) was appar-
ently due to the marked decrease in Car. These rats also had a
degree of lysozymuria (1863 321 cg/day), a tubular necrosis
score (3.9 0.1) and renal cortical gentamicin accumulation
(360 20 pglg wet tissue) not different from that of Group III
animals. Thus, normoglycemic glycosuric rats were not pro-
tected against the nephrotoxic effects of gentamicin.
The response of the rats with mild DM (Group IV) to
gentamicin was markedly different, with a significant attenua-
tion of the nephrotoxic effects of gentamicin being clearly
apparent. By day 9, these animals failed to exhibit any signifi-
cant deterioration of kidney function, as shown by a plasma
creatinine level of 0.28 0.04 mg/dl and a CCr value of 1.8 0.1
mI/mm, both values not significantly different from baseline.
Only one of the five rats in this group developed late lysozym-
uria, and the tubular necrosis score for the group was 0.8 0.4.
The individual histologic analysis of these animals revealed that
two had no evidence of tubular injury, and that moderate
necrosis (grade 2) was present in one, with the other two
animals showing only minimal alterations (grade 1). The amount
of gentamicin accumulated in the kidney cortex was 493 55
cgIg wet tissue, a value not statistically different from that
measured in the other groups. Furthermore, whereas Group IV
rats gained body weight at the same rate as those of Group I
animals (Table 2), the others either did not gain (Group II) or
lost (Group III, P < 0.001) weight. Thus, although initial Car,
urine volume, and osmolal clearances were similar between the
two groups with comparable glycosuria, severe ARF after
gentamicin administration developed only in the phlorizin-
treated animals, whereas negligible changes were exhibited by
the DM rats.
Discussion
Our laboratory has developed a model in which complete
functional and morphological protection against gentamicin-
induced ARF is observed in untreated diabetic rats [1—31. We
suggested that the marked glycosuria with its accompanying
osmotic effects reduces the tubular incorporation of gentamicin,
thereby limiting cellular damage [1, 21.
In the current experiments, we evaluated more directly the
possible protective effect of enhanced glucose excretion upon
the natural history of gentamicin-ARF in the rat. Renal glycos-
4,
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diabetes
gentamicin +
gentamicin
Fig. 3. Maximal changes in creatinine clearance (% change from
baseline), peak lysozymuria (pg/day), tubular necrosis score, and renal
cortical gentamicin (g/g wet tissue) after 9 days of gentamicin
administration. All groups but Group I (phlonzin alone) were injected
daily for 9 days with gentamicin sulfate at a dose of 40 mg/kg/day. See
Methods section for explanation of the tubular necrosis score. The
asterisks indicate that lysozymuria was undetectable or that the tubular
necrosis score was zero. The vertical bars represent one SEM.
uria was induced with phlorizin in non-diabetic rats; the ensuing
glycosuria failed to confer protection against gentamicin-in-
duced ARF. In marked contrast, diabetic animals undergoing a
similar degree of glycosuria exhibited marked functional and
morphologic protection against gentamicin ARF.
Whereas the acute effects of phlorizin on renal function have
been well delineated [17—19], few investigators have studied the
effects of its chronic administration. Freely filtered phlonzin
(phloretin 2-glucoside) inhibits the transport of glucose into the
proximal renal tubules by competitive inhibition of the glucose
carrier [12, 20]. Christlieb and Long [21] injected phlorizin
chronically into rats with alloxan-induced diabetes to evaluate
the activation of the renin-angiotensin system. After 18 days of
continued phlorizin administration no changes in BUN were
observed. To our knowledge, no detailed analysis of the long-
te.m effects of phlorizin on kidney function or morphology have
been reported.
In the present study, four days after the initiation of phlorizin
injections, moderate renal glycosuria, mild polyuria and natri-
uresis, and marked elevation of osmolal clearance developed
(Table 1). These changes were accompanied by appropriate
increases in water and food intake, and normal growth. Phlori-
zin was non-toxic to the renal tubules as shown by the absence
of lysozymuria and preservation of normal tubular architecture
after 15 days of continued administration. None of the hydropic
changes observed in proximal tubular epithelium of animals
undergoing osmotic diuresis with mannitol [22] were seen in
these animals.
Phlorizin, when given intravenously to anesthetized rats,
induces an acute fall in whole kidney [18] and single nephron
GFR (SNGFR) [191. Either a direct interference with the
tubuloglomerular feedback mechanism, and/or a direct depres-
sive effect on myocardial function were postulated as likely
explanations [18]. In contrast, the continued administration of
phlorizin to our Group I animals, was associated with a steady
and substantial elevation of C. together with a significant
decrease in plasma creatinine levels (Table 1, Fig 2). We have
observed similar findings in diabetic hyperglycemic glycosuric
rats [1, 3]. Blantz et al [23] reported that anesthetized rats
exhibited an increase in whole kidney GFR and SNGFR when
modest hyperglycemia was induced acutely. The increase in
SNGFR appeared to be accounted for solely by the decrease in
systemic oncotic pressure due to reductions in plasma protein
concentration. In addition, these investigators [24] demon-
strated that during acute modest hyperglycemia, the tubulo-
glomerular feedback response to an increase in late proximal
tubular flow rate was inhibited. That is, SNGFR did not
decrease with large increases in proximal tubule flow rate.
Taken together, these two observations [23, 24] might explain
the increased GFR that we have observed in hyperglycemic
glycosuric DM rats [1, 3]. Nevertheless, since our glycosuric
Group I animals were normoglycemic throughout the study, we
have no explanation for their increased GFR.
Whereas in other models of ARF, the protective role of
volume expansion and the resulting enhanced solute excretion
appears better established [25—28], this has not been convinc-
ingly demonstrated in the case of gentamicin [29]. The admin-
istration of a high sodium intake prior to gentamicin treatment,
however, can attenuate aminoglycoside-induced decreases in
GFR [27]. The effect of an osmotic diuresis on gentamicin-
induced ARF was studied by Newman et al in the rat drinking
isosorbide [7]. These investigators failed to demonstrate any
reduction in the amount of gentamicin accumulated in the renal
cortex or any amelioration of tubular damage, Likewise, Elliott
et al [5] reported recently that gentamicin nephrotoxicity was of
similar magnitude in non-diabetic male Fischer 344 rats under-
going an isosorbide osmotic diuresis when compared to non-
diuretic animals. Streptozotocin-treated rats, however, exhib-
ited amelioration of the toxic functional and morphologic effects
of the aminoglycoside [5], indicating that solute diuresis in the
diabetic group did not protect against gentamicin. Unfortu-
nately, these investigators did not provide data comparing the
50
25
'O 0
25
50
100
3000
1500
E
>.N0
-J 0
a
0
C.)
C.Q 3U,
U,0
2a
C
I- 0
600
: 400
E
'V
C
a,
2' 200
Ca
C.)
0Ci
CaCa
+
Gouvea et al: Glycosuria and gentamicin nephrotoxicity 1047
solute excretion or urine flow rates between the glycosuric and
non-glycosuric groups.
The protected DM rats in the current study had higher rates
of sodium excretion than did the unprotected animals in Groups
II and III (Table 2), and this might have influenced the results.
The range of their values (about 0.7 mEq/day/lOO g body wt),
however, were four to eight times lower than those reported in
animals drinking saline (3 to 6 mEq/day/lOO g body wt), which
exhibited protection from other nephrotoxins, such as glycerol,
uranyl nitrate, and mercuric chloride [30—32]. Furthermore,
under the experimental conditions of the study urinary flow
rates (and presumably tubular flow rates) were not different
between Groups II and IV (Table 2). Thus, it is safe to conclude
that high tubular, urinary flow, and sodium excretion rates
cannot explain the difference in the nephrotoxic response to
gentamicin observed between the two groups.
In the present study, renal glycosuria did not influence the
uptake and subsequent transport of gentamicin into proximal
tubular cells. The accumulation of gentamicin in the renal
cortex was similar in non-glycosuric (Group III) and glycosuric
(Group II) rats which exhibited similar degrees of tissue damage
and renal dysfunction in response to gentamicin (Fig 3). More-
over, phlorizin specifically competes with glucose for the bind-
ing sites in the brush border membrane of the proximal tubule
[18, 33]. Therefore, it may be concluded that the cellular uptake
of gentamicin occurs through mechanisms other than those
associated with glucose transport. Indeed, rats with normal
baseline renal glucose transport (control rats in studies cited in
[1—3]), with completely abolished transport (Group III) or with
normal or slightly elevated transport (Group IV), have different
nephrotoxic responses to gentamicin administration. These
data are in agreement with in vitro [34], and in vivo studies [35].
In the latter, microperfusion of the proximal tubules with
increasing concentrations of glucose did not cause a reduction
in the absorptive flux of gentamicin. The authors [35] suggested
that the decreased transport of the aminoglycoside seen in
diabetic rats [1, 2] might be an inherent characteristic of the
diabetic state.
Correction of diabetes with therapeutic doses of insulin
renders the DM rat susceptible to the nephrotoxic effects of
gentamicin [13]. In the current experiments, we found that
low-dose insulin administration and partial correction of diabe-
tes was associated with the appearance of late and minimal
evidence of nephrotoxicity (Fig 3). This indicated that the
factor(s) responsible for the protection in diabetes was still
operative despite sub-therapeutic insulin treatment.
Possible explanations for not observing a lower tissue con-
centration of gentamicin in the rats with mild diabetes (Group
IV) than in Groups II and III animals can be advanced. Based
on our previous findings of altered phosphatidylinositol metab-
olism in DM rats [36] and its normalization with insulin treat-
ment [13], we might speculate that the putative receptors for
gentamicin in the renal cortex of mildly DM rats were increased
by insulin therapy, and thus, resulted in more gentamicin
transported and a higher accumulation into tubular cells. A
recent study [37], however, reported no difference between the
phospholipid composition or the netilmicin or gentamicin bind-
ing constants of renal brush border and basolateral membrane
vesicles from diabetic and nondiabetic rats, making the above
suggestion unlikely. A more plausible possibility is that by
harvesting the kidneys for gentamicin assay at the height of
renal tissue injury (day 9 of gentamicin therapy), we may have
underestimated the cortical levels of the aminoglycoside in the
rats with renal failure (Groups II and III). This may result from
tissue edema, necrosis and/or loss of cellular debris laden with
gentamicin into the urine, as previously suggested [1, 5, 291.
Finally, it also should be noted, that in some animal models (rat,
rabbit), the renal handling and toxicity of gentamicin is some-
what dissociated from the tissue levels of this antibiotic in
studies aimed at comparing the nephrotoxicity of gentamicin to
that of other aminoglycosides [38, 39].
Early biochemical cellular changes and a subsequent reduc-
tion of GFR characterize the natural history of experimentally-
induced gentamicin ARF. This interpretation is consistent with
the features of gentamicin nephrotoxicity in humans [40—42].
The experimental and clinical evidence supporting the primary
cellular changes, such as lysosomal phospholipidosis [40—44],
labilization of lysosomes [42, 43], impaired mitochondrial res-
piration [45] has accumulated rapidly. It is not yet clear, how-
ever, how these cellular events ultimately lead to the reduction
in GFR and appearance of ARF.
In summary, phlorizin induces a moderate glycosuria and
diuresis and has no nephrotoxic action when given for 15 days.
Phlorizin does not interfere with the uptake of gentamicin by
the proximal tubular cells, nor does it lessen the acute renal
failure and tubular necrosis that follows the administration of
gentamicin. Protection against gentamicin-acute renal failure
was demonstrated in diabetic rats with mild glycosuria of a
degree similar to that of phlorizin-treated rats. This protection
was independent of the degree of glycosuria, solute diuresis,
and urine flow rate associated with mild diabetes. We conclude
that glycosuria per se (and/or altered glucose transport), and
solute diuresis cannot explain the morphologic and functional
protection against gentamicin-induced acute renal failure shown
by untreated diabetic rats.
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